Association between lipid profile and risk of atrial fibrillation: Niigata preventive medicine study

Circulation Journal

Volumn 75, Issue 12, 2011, Pages 2767-2774

  Watanabe, Hiroshi ^a   Tanabe, Naohito ^b   Yagihara, Nobue ^a   Watanabe, Toru ^c   Aizawa, Yoshifusa ^a   Kodama, Makoto ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF NIIGATA PREFECTURE   (Japan)

^c Niigata Health Foundation   (Japan)

Author keywords

Atrial fibrillation; Cholesterol; Dyslipidemia; Epidemiology; Risk factors

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; CHOLESTEROL, HDL; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 82455177870     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0780     Document Type: Article

References (45)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
2. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-777.
3. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
4. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
5. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circulation 2008; 117: 1255-1260.
6. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology 1999; 92: 21-27.
7. Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008; 72: 909-913.
8. Diaz-Peromingo JA, Alban-Salgado A, Garcia-Suarez F, Sanchez-Leira J, Saborido-Frojan J, Iglesias-Gallego M. Lipoprotein(a) and lipid profile in patients with atrial fibrillation. Med Sci Monit 2006; 12: CR122-CR125.
9. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54: 2023-2031.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
11. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81: 26B-31B.
12. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
13. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-646.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
15. Eriksson H, Svardsudd K, Larsson B, Ohlson LO, Tibblin G, Welin L, et al. Risk factors for heart failure in the general population: The study of men born in 1913. Eur Heart J 1989; 10: 647-656.
16. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: The Framingham Heart Study. Circulation 2009; 120: 2345-2351.
17. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 2001; 19: 2265-2270.
18. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 2003; 16: 938-944.
19. Wang TD, Lee CM, Wu CC, Lee TM, Chen WJ, Chen MF, et al. The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis 1999; 146: 117-124.
20. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
21. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-180.
22. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150: 1064.
23. Patel AA, White CM, Shah SA, Dale KM, Kluger J, Coleman CI. The relationship between statin use and atrial fibrillation. Curr Med Res Opin 2007; 23: 1177-1185.
24. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009; 73: 2244-2249.
25. Takagi H, Umemoto T. Effect of preoperative statin therapy on postoperative atrial fibrillation in cardiac surgery. Circ J 2010; 74: 2788-2789; author reply 2790.
26. Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: Role of nitric oxide and superoxide. Free Radic Biol Med 2002; 33: 1026-1036.
27. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004; 52: 1639-1647.
28. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, et al. Lowdensity lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: The Ibaraki Prefectural Health Study. Circulation 2009; 119: 2136-2145.
29. Takayama Y. Effects of an atherogenic diet on arterial lesions of hypertensive rats. J Jpn Coll Angiol 1975; 15: 455-464.
30. Vatassery GT, Smith WE, Quach HT, Lai JC. In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Neurochem Int 1995; 26: 527-535.
31. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet 2009; 373: 739-745.
32. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477.
33. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population- based cohort: The Framingham Heart Study. JAMA 1994; 271: 840-844.
34. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
35. Inoue H, Nozawa T, Hirai T, Goto S, Origasa H, Shimada K, et al. Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE. Circ J 2010; 74: 650-654.
36. Suttorp MJ, Kingma JH, Koomen EM, van't Hof A, Tijssen JG, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71: 710-713.
37. Tse HF, Oral H, Pelosi F, Knight BP, Strickberger SA, Morady F. Effect of gender on atrial electrophysiologic changes induced by rapid atrial pacing and elevation of atrial pressure. J Cardiovasc Electrophysiol 2001; 12: 986-989.
38. Iguchi Y, Kimura K, Shibazaki K, Aoki J, Kobayashi K, Sakai K, et al. Annual incidence of atrial fibrillation and related factors in adults. Am J Cardiol 2010; 106: 1129-1133.
39. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA 2010; 304: 2363-2372.
40. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
41. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: The SAFE study. Health Technol Assess 2005; 9: iii-iv, ix-x, 1-74.
42. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
43. Ingelsson E, Massaro JM, Sutherland P, Jacques PF, Levy D, D'Agostino RB, et al. Contemporary trends in dyslipidemia in the Framingham Heart Study. Arch Intern Med 2009; 169: 279-286.
44. Anuurad E, Shiwaku K, Enkhmaa B, Nogi A, Kitajima K, Yamasaki M, et al. Ethnic differences in the formation of small LDL particles in Asians: A comparison of Koreans, Japanese and Mongolians. Eur J Clin Invest 2004; 34: 738-746.
45. Diez Roux AV, Detrano R, Jackson S, Jacobs DR Jr, Schreiner PJ, Shea S, et al. Acculturation and socioeconomic position as predictors of coronary calcification in a multiethnic sample. Circulation 2005; 112: 1557-1565.